237 related articles for article (PubMed ID: 23197299)
1. Thrombin-activatable fibrinolysis inhibitor in hypothyroidism and hyperthyroxinaemia.
Verkleij CJ; Stuijver DJ; van Zaane B; Squizzato A; Brandjes DP; Büller HR; Meijers JC; Gerdes VE
Thromb Haemost; 2013 Feb; 109(2):214-20. PubMed ID: 23197299
[TBL] [Abstract][Full Text] [Related]
2. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
Colucci M; Binetti BM; Branca MG; Clerici C; Morelli A; Semeraro N; Gresele P
Hepatology; 2003 Jul; 38(1):230-7. PubMed ID: 12830006
[TBL] [Abstract][Full Text] [Related]
3. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
Ermantas N; Guldiken S; Demir M; Tugrul A
Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
[TBL] [Abstract][Full Text] [Related]
4. Prothrombotic alterations in plasma fibrin clot properties in thyroid disorders and their post-treatment modifications.
Mazur P; Sokołowski G; Hubalewska-Dydejczyk A; Płaczkiewicz-Jankowska E; Undas A
Thromb Res; 2014 Aug; 134(2):510-7. PubMed ID: 24962680
[TBL] [Abstract][Full Text] [Related]
5. Effect of heparin on TAFI-dependent inhibition of fibrinolysis: relative importance of TAFIa generated by clot-bound and fluid phase thrombin.
Colucci M; Pentimone A; Binetti BM; Cramarossa M; Piro D; Semeraro N
Thromb Haemost; 2002 Aug; 88(2):282-7. PubMed ID: 12195701
[TBL] [Abstract][Full Text] [Related]
6. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation.
Mosnier LO; von dem Borne PA; Meijers JC; Bouma BN
Thromb Haemost; 1998 Nov; 80(5):829-35. PubMed ID: 9843179
[TBL] [Abstract][Full Text] [Related]
7. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
[TBL] [Abstract][Full Text] [Related]
8. Factor IX-Padua enhances the fibrinolytic resistance of plasma clots.
Ammollo CT; Semeraro F; Colucci M; Simioni P
Thromb Haemost; 2014 Feb; 111(2):226-32. PubMed ID: 24136406
[TBL] [Abstract][Full Text] [Related]
9. Thrombin activatable fibrinolysis inhibitor (TAFI)--how does thrombin regulate fibrinolysis?
Bouma BN; Mosnier LO
Ann Med; 2006; 38(6):378-88. PubMed ID: 17008302
[TBL] [Abstract][Full Text] [Related]
10. Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway.
Colucci M; Incampo F; Cannavò A; Menegatti M; Siboni SM; Zaccaria F; Semeraro N; Peyvandi F
J Thromb Haemost; 2016 Aug; 14(8):1603-14. PubMed ID: 27094709
[TBL] [Abstract][Full Text] [Related]
11. [The TAFI system. The new role of fibrinolysis].
Dempfle CE
Hamostaseologie; 2007 Sep; 27(4):278-81. PubMed ID: 17938767
[TBL] [Abstract][Full Text] [Related]
12. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
Guimarães AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
13. [Thrombin activatable fibrinolysis inhibitor (TAFI) and its importance in the regulation of fibrinolysis].
Stasko J; Hudecek J; Kubisz P
Vnitr Lek; 2004 Jan; 50(1):36-44. PubMed ID: 15015228
[TBL] [Abstract][Full Text] [Related]
14. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis.
Martini CH; Brandts A; de Bruijne EL; van Hylckama Vlieg A; Leebeek FW; Lisman T; Rosendaal FR
Br J Haematol; 2006 Jul; 134(1):92-4. PubMed ID: 16803573
[TBL] [Abstract][Full Text] [Related]
15. Thrombin activatable fibrinolysis inhibitor: at the nexus of fibrinolysis and inflammation.
Colucci M; Semeraro N
Thromb Res; 2012 Mar; 129(3):314-9. PubMed ID: 22113149
[TBL] [Abstract][Full Text] [Related]
16. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration.
Mosnier LO; Lisman T; van den Berg HM; Nieuwenhuis HK; Meijers JC; Bouma BN
Thromb Haemost; 2001 Oct; 86(4):1035-9. PubMed ID: 11686321
[TBL] [Abstract][Full Text] [Related]
17. A functional assay for measuring activated thrombin-activatable fibrinolysis inhibitor in plasma.
Neill EK; Stewart RJ; Schneider MM; Nesheim ME
Anal Biochem; 2004 Jul; 330(2):332-41. PubMed ID: 15203340
[TBL] [Abstract][Full Text] [Related]
18. Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy.
Małyszko J; Małyszko JS; Hryszko T; Myśliwiec M
Thromb Haemost; 2004 Mar; 91(3):480-6. PubMed ID: 14983223
[TBL] [Abstract][Full Text] [Related]
19. Thrombin activatable fibrinolysis inhibitor (TAFI): a role in pre-eclampsia?
Dusse LM; Cooper AJ; Lwaleed BA
Clin Chim Acta; 2007 Mar; 378(1-2):1-6. PubMed ID: 17184758
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms.
Mishra N; Vercauteren E; Develter J; Bammens R; Declerck PJ; Gils A
Thromb Haemost; 2011 Jul; 106(1):90-101. PubMed ID: 21544309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
